|
KR20210014289A
|
|
Manufacturing method of sustained release rasagiline microsphere
|
|
KR20180117883A
|
|
A device for manufacturing sustained-release microspheres comprising drug and a manufacturing method using the device
|
|
KR20160019020A
|
|
A method for producing drug-containing sustained release micro particle
|
|
KR20160019022A
|
|
A method for producing micro particle for biodegradable filler
|
|
KR20130020760A
|
|
Tablet containing granulocyte macrophage-colony stimulating factor
|
|
KR101312286B1
|
|
Pharmaceutical composition having immediate release and controlled release properties and comprising d-threo-methylphenidate
|
|
KR101301700B1
|
|
Pharmaceutical composition for treating tuberculosis comprising rifampicin with improved solubility and stability and method for preparing the same
|
|
KR101251625B1
|
|
Novel manufacturing method of dutasteride using novel intermediates
|
|
KR20130120118A
|
|
Gastroretentive sustained release formulation with bilayer structure
|
|
KR101093787B1
|
|
Pharmaceutical composition for treating cancer comprising new derivatives of nucleosides
|
|
WO2012169677A1
|
|
Composition for controlling gastric retention and release
|
|
KR101093781B1
|
|
Solid pharmaceutical composition of moxifloxacin comprising ph adjustment agent
|
|
KR101139431B1
|
|
New method for producing imatinib base
|
|
KR20120112689A
|
|
Pharmaceutical composition comprising metformin and rosuvastatin
|
|
KR101111534B1
|
|
Composition for Orally disintegrating tablet and process for obtaining thereof
|
|
KR101055412B1
|
|
Composition for self-emulsifying preparation comprising dutasteride and manufacturing process thereof
|
|
KR20120051328A
|
|
Novel derivatives of nucleosides
|
|
KR20110123178A
|
|
Composition for the gastric retention and controlled release of therapeutic agents
|
|
KR20110106720A
|
|
NOVEL PROCESS FOR THE PREPARATION OF RACEMIC MIXTURE, D-FORM OR L-alpha;-GLYCERYL PHOSPHORYLCHOLINE
|
